Profile data is unavailable for this security.
About the company
CRISPR Therapeutics AG is a Switzerland-based gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) and is a technology for gene editing, the process of precisely altering specific sequences of genomic DNA. The Company aims to apply this technology to disrupt, delete, correct and insert genes to treat genetically-defined diseases and to engineer advanced cellular therapies. The Company has acquired the rights to the intellectual property (IP) encompassing CRISPR/Cas9 and related technologies and is also involved in its own IP research and additional in-licensing efforts. The Company product development and partnership strategies are designed to exploit the full potential of the CRISPR/Cas9 platform while maximizing the probability of successfully developing their product candidates.
- Revenue in USD (TTM)271.71m
- Net income in USD-217.14m
- Incorporated2013
- Employees407.00
- LocationCRISPR Therapeutics AGBaarerstrasse 14ZUG 6300SwitzerlandCHE
- Phone+41 415613279
- Websitehttps://crisprtx.com/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Merus NV | 38.34m | -149.65m | 3.59bn | 172.00 | -- | 8.94 | -- | 93.56 | -2.72 | -2.72 | 0.7031 | 5.95 | 0.0917 | -- | 1.21 | 222,889.50 | -35.78 | -29.35 | -43.82 | -35.36 | -- | -- | -390.36 | -252.21 | -- | -- | 0.00 | -- | 5.68 | 2.75 | -18.10 | -- | -1.73 | -- |
| Immunovant Inc | 0.00 | -259.34m | 3.71bn | 207.00 | -- | 5.98 | -- | -- | -1.89 | -1.89 | 0.00 | 4.24 | 0.00 | -- | -- | 0.00 | -48.37 | -- | -52.91 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -22.93 | -- | -- | -- |
| Simply Good Foods Co | 1.27bn | 140.76m | 3.85bn | 271.00 | 27.63 | 2.34 | 23.77 | 3.04 | 1.39 | 1.39 | 12.53 | 16.48 | 0.5977 | 6.91 | 8.56 | 4,671,908.00 | 6.65 | 3.66 | 6.95 | 3.83 | 37.26 | 38.90 | 11.12 | 6.80 | 3.09 | 9.26 | 0.1261 | 0.00 | 6.33 | 23.56 | 23.03 | 13.65 | 47.09 | -- |
| Alkermes Plc | 1.73bn | 599.95m | 3.96bn | 2.10k | 6.68 | 3.16 | 5.96 | 2.29 | 3.50 | 2.53 | 10.05 | 7.42 | 0.8532 | 1.32 | 5.81 | 821,991.40 | 29.65 | 1.34 | 38.77 | 1.74 | 85.31 | 83.32 | 34.76 | 2.12 | 2.77 | -- | 0.1878 | 0.00 | 49.61 | 8.74 | 1,665.99 | -- | -7.10 | -- |
| Hims & Hers Health Inc | 959.40m | -2.35m | 4.17bn | 1.05k | -- | 12.09 | 518.28 | 4.35 | -0.0145 | -0.0145 | 4.46 | 1.61 | 2.33 | 6.68 | 176.36 | 917,209.40 | -0.5704 | -- | -0.6968 | -- | 82.41 | -- | -0.245 | -- | 2.48 | -- | 0.00 | -- | 65.49 | -- | 64.15 | -- | -- | -- |
| Alvotech SA | 114.39m | -494.28m | 4.20bn | 999.00 | -- | -- | -- | 36.73 | -2.05 | -2.05 | 0.4909 | -2.47 | 0.117 | 1.69 | 1.97 | 114,507.50 | -50.54 | -- | -63.82 | -- | -23.89 | -- | -432.09 | -- | 0.8107 | -1.26 | 2.49 | -- | 9.84 | -- | -7.43 | -- | -- | -- |
| Nuvalent Inc | 0.00 | -145.51m | 4.24bn | 106.00 | -- | 6.27 | -- | -- | -2.41 | -2.41 | 0.00 | 10.47 | 0.00 | -- | -- | 0.00 | -24.88 | -- | -26.01 | -- | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | -54.20 | -- | -- | -- |
| Immunitybio Inc | 302.00k | -600.96m | 4.44bn | 628.00 | -- | -- | -- | 14,701.54 | -1.05 | -1.05 | 0.0005 | -1.02 | 0.0008 | -- | 0.1677 | 480.89 | -161.65 | -112.76 | -946.50 | -316.07 | -- | -- | -199,138.70 | -37,700.74 | -- | -1.92 | 5.32 | -- | 159.17 | 67.62 | -40.00 | -- | 18.48 | -- |
| Crispr Therapeutics AG | 271.71m | -217.14m | 4.56bn | 407.00 | -- | 2.19 | -- | 16.80 | -2.70 | -2.70 | 3.40 | 24.56 | 0.116 | -- | -- | 667,592.10 | -9.27 | -7.66 | -9.83 | -8.06 | -- | -- | -79.91 | -44.88 | -- | -- | 0.00 | -- | 30,885.48 | 160.00 | 76.37 | -- | 33.98 | -- |
| Krystal Biotech Inc | 95.95m | 57.16m | 4.57bn | 229.00 | 85.04 | 5.71 | 72.06 | 47.64 | 1.88 | 1.88 | 3.38 | 28.02 | 0.1385 | -- | -- | 418,991.30 | 8.25 | -11.50 | 8.78 | -12.01 | 94.25 | -- | 59.57 | -492.85 | 12.42 | -- | 0.00 | -- | -- | -- | 107.81 | -- | 39.49 | -- |
| Apellis Pharmaceuticals Inc | 524.07m | -417.27m | 4.76bn | 702.00 | -- | 17.85 | -- | 9.09 | -3.46 | -3.46 | 4.33 | 2.20 | 0.5788 | 0.5747 | 3.50 | 746,538.40 | -46.09 | -73.88 | -57.28 | -90.03 | 86.47 | -- | -79.62 | -326.49 | 3.02 | -39.71 | 0.6087 | -- | 425.83 | -- | 18.94 | -- | -- | -- |
| Madrigal Pharmaceuticals Inc | 0.00 | -444.28m | 5.03bn | 376.00 | -- | 5.74 | -- | -- | -23.08 | -23.08 | 0.00 | 41.13 | 0.00 | -- | -- | 0.00 | -62.81 | -62.09 | -73.92 | -74.81 | -- | -- | -- | -- | 9.39 | -- | 0.1201 | -- | -- | -- | -26.50 | -- | 132.01 | -- |
| BridgeBio Pharma Inc | 218.60m | -538.26m | 5.24bn | 550.00 | -- | -- | -- | 23.98 | -3.23 | -3.23 | 1.29 | -5.61 | 0.2964 | -- | -- | 397,449.10 | -74.13 | -72.44 | -90.19 | -89.72 | 98.91 | 94.41 | -250.09 | -1,225.66 | -- | -11.48 | 2.53 | -- | -88.02 | -- | -33.67 | -- | -40.94 | -- |
| Ionis Pharmaceuticals Inc | 776.62m | -384.77m | 5.48bn | 927.00 | -- | 18.48 | -- | 7.06 | -2.67 | -2.67 | 5.40 | 2.03 | 0.275 | 0.379 | 81.52 | 837,777.80 | -13.62 | -6.30 | -15.20 | -7.44 | 98.72 | 98.75 | -49.54 | -21.23 | 7.28 | -- | 0.8114 | -- | 34.10 | 5.60 | -35.80 | -- | 11.83 | -- |
| Organon & Co | 6.35bn | 1.05bn | 5.49bn | 10.00k | 5.23 | 113.69 | 4.25 | 0.8643 | 4.08 | 4.08 | 24.71 | 0.1876 | 0.5603 | 2.18 | 4.24 | 634,700.00 | 9.24 | 16.53 | 11.79 | 20.97 | 59.04 | 65.12 | 16.50 | 26.79 | 1.15 | 2.36 | 0.9945 | 8.25 | 1.44 | -8.52 | 11.56 | -13.83 | 20.72 | -- |
| Cytokinetics, Inc. | 3.75m | -530.60m | 5.56bn | 423.00 | -- | -- | -- | 1,481.39 | -5.40 | -5.40 | 0.0382 | -3.78 | 0.0044 | -- | 4.08 | 8,869.98 | -62.50 | -43.14 | -69.19 | -47.22 | -- | -- | -14,141.74 | -540.47 | -- | -15.26 | 2.78 | -- | -92.04 | -24.89 | -35.30 | -- | 9.76 | -- |
Data as of May 31 2024. Currency figures normalised to CRISPR Therapeutics AG's reporting currency: US Dollar USD
40.29%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| ARK Investment Management LLCas of 31 Mar 2024 | 8.16m | 9.61% |
| Capital Research & Management Co. (International Investors)as of 31 Mar 2024 | 7.84m | 9.23% |
| Nikko Asset Management Americas, Inc.as of 31 Mar 2024 | 3.27m | 3.85% |
| Nikko Asset Management Co., Ltd.as of 31 Mar 2024 | 3.27m | 3.85% |
| T. Rowe Price Investment Management, Inc.as of 31 Mar 2024 | 2.70m | 3.19% |
| BlackRock Fund Advisorsas of 31 Mar 2024 | 2.30m | 2.71% |
| Fidelity Management & Research Co. LLCas of 31 Mar 2024 | 2.24m | 2.64% |
| The Vanguard Group, Inc.as of 31 Mar 2024 | 1.54m | 1.81% |
| SSgA Funds Management, Inc.as of 31 Mar 2024 | 1.50m | 1.76% |
| EcoR1 Capital, LLCas of 31 Mar 2024 | 1.39m | 1.64% |
More ▼
Data from 31 Mar 2024 - 31 Mar 2024Source: FactSet Research Systems Inc.
